nach oben

Journal für Mineralstoffwechsel & Muskuloskelettale Erkrankungen

Erschienen in:

01.03.2018 | Science in CEE countries

Etidronic acid and its calcium-comprising complexes in the treatment of experimental osteoporosis in estrogen-deficient rats

verfasst von: V. V. Povoroznyuk, N. V. Grygorieva, V. I. Pekhnyo, H. Resch, O. M. Kozachkova, N. V. Tsaryk

Erschienen in: Journal für Mineralstoffwechsel & Muskuloskelettale Erkrankungen | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Aim

The aim of this study was to investigate the composition, stability, and biological activity of the complexes formed in solution upon interaction of calcium (Ca) ions with etidronic acid (EA), and to compare their effects on bone mineral density (BMD) in estrogen-deficient rats with osteoporosis.

Materials and methods

The study was conducted on 40 female Wistar rats. Osteoporosis was modeled by bilateral oophorectomy and therapy was started 4 months after surgery. Four groups were under study: the first group did not receive any osteoporotic treatment, only supplementation of Ca/vitamin D (D) in their diet. The second group received a single parenteral dose of EA with Ca/D supplementation. The third group received a Ca complex of EA (Ca-EA) without additional use of Ca/D. The fourth group received Ca-EA with Ca/D. Bone parameters (BMD and bone mineral content [BMC] in spine and total body) were measured by X‑ray densitometry using Prodigy (GE Medical systems, Model 8743, 2005; USA; program “Experimental animals”) thrice (before treatment, after 1 and 3 months of follow-up).

Results

Therapy with EA and Ca/D showed significant differences in total body BMD (tbBMD) only after 3 months. We established reliable changes in spine BMD (sBMD) and tbBMD after 1 and 3 months of treatment in group 3 rats: administration of Ca-EA with Ca/D had positive effects on sBMD at 1 and 3 months, and on tbBMD after 3 months. We did not establish any significant changes between sBMD and tbBMD after 1 and 3 months of therapy dependent on additional Ca/D supplementation (groups 3 and 4).

Conclusion

We showed a positive effect of the studied Ca-EA complexes on the BMD and BMC indices, with or without additional supplementation of Ca/D. More explicit dynamics of indices were observed in the group of animals treated with Ca-EA without additional Ca/D after 1 and 3 months of follow-up.

Vorheriger Artikel 4th Central and Eastern European Summit on Bone Diseases 2017

Nächster Artikel Fibröse Dysplasie

Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster J‑Y, Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO), Committee of Scientific Advisors of the International Osteoporosis Foundation (IOF) (2013) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 24:23–57. https://doi.org/10.1007/s00198-012-2074-y CrossRefPubMed

Camacho PM, Peak SM, Binkley N, Clarke BL, Harris ST, Hurley DL, Kleerekoper M, Lewiecki EM, Miller PD, Narula HS, Pessah-Pollack R, Tangpricha V, Wimalawansa SJ, Watts NB (2016) American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for the diagnosis and treatment of postmenopausal osteoporosis—2016—Executive Summary. Endocr Pract 22(9):1111–1118. https://doi.org/10.4158/EP161435.ESGL CrossRefPubMed

Povoroznyuk VV, Grygorieva NV, Orlyk TV et al (2014) Osteoporosis in the practice of internist doctor. Express, Kyiv (Russian)

Chan CK, Mason A, Cooper C, Dennison E (2016) Novel advances in the treatment of osteoporosis. Br Med Bull 119(1):129–142. https://doi.org/10.1093/bmb/ldw033 CrossRefPubMedPubMedCentral

Moore SN, Tanner SB, Schoenecker JG (2015) Bisphosphonates: from softening water to treating PXE. Cell Cycle 14(9):1354–1355. https://doi.org/10.1080/15384101.2015.1024585 CrossRefPubMedPubMedCentral

Russell RG (2011) Bisphosphonates: the first 40 years. Bone 49(1):2–19. https://doi.org/10.1016/j.bone.2011.04.022 CrossRefPubMed

Ebetino FH, Hogan AM, Sun S, Tsoumpra MK, Duan X, Triffitt JT, Kwaasi AA, Dunford JE, Barnett BL, Oppermann U, Lundy MW, Boyde A, Kashemirov BA, McKenna CE, Russell RG (2011) The relationship between the chemistry and biological activity of the bisphosphonates. Bone 49(1):20–33. https://doi.org/10.1016/j.bone.2011.03.774 CrossRefPubMed

Zhou J, Ma X, Wang T, Zhai S (2016) Comparative efficacy of bisphosphonates in short-term fracture prevention for primary osteoporosis: a systematic review with network meta-analyses. Osteoporos Int 27(11):3289–3300. https://doi.org/10.1007/s00198-016-3654-z CrossRefPubMed

Amiche MA, Albaum JM, Tadrous M, Pechlivanoglou P, Lévesque LE, Adachi JD, Cadarette SM (2016) Efficacy of osteoporosis pharmacotherapies in preventing fracture among oral glucocorticoid users: a network mEA-analysis. Osteoporos Int 27(6):1989–1998. https://doi.org/10.1007/s00198-015-3476-4 CrossRefPubMed

10.

Tartari T, Guimarães BM, Amoras LS, Duarte MA, e Souza SPA, Bramante CM (2015) Etidronate causes minimal changes in the ability of sodium hypochlorite to dissolve organic matter. Int Endod J 48(4):399–404. https://doi.org/10.1111/iej.12329 CrossRefPubMed

11.

Council of Europe (1986) European convention for the protection of vertebrate animals used for experimental and other scientific purpose: Council of Europe 18.03.1986. Council of Europe, Strasbourg

12.

Povoroznyuk VV, Deduh NV, Grygorieva NV, Gopkalova IV (2012) Experimental osteoporosis. Express, Kyiv (Russian)

13.

Afonin EG, Aleksandrov GG, Ilyinsky AL (2000) Diprotonated 1‑hydroxyethane-1,1-diphosphonate of calcium. Russ J Inorg Chem 45(6):961–966

14.

Gómez-Alcántara MM, Cabeza A, Martínez-Lara M, Aranda MA, Suau R, Bhuvanesh N, Clearfield A (2004) Synthesis and characterization of a new bisphosphonic acid and several mEAl hybrids derivatives. Inorg Chem 43(17):5283–5293CrossRefPubMed

15.

De Colli M, Tortorella P, Marconi GD, Agamennone M, Campestre C, Tauro M, Cataldi A, Zara S (2016) In vitro comparison of new bisphosphonic acids and zoledronate effects on human gingival fibroblasts viability, inflammation and matrix turnover. Clin Oral Investig 20(8):2013–2021CrossRefPubMed

16.

Ferrer-Casal M, Li C, Galizzi M, Stortz CA, Szajnman SH, Docampo R, Moreno SNJ, Rodriguez JB (2014) New insights into molecular recognition of 1,1-bisphosphonic acids by farnesyl diphosphate synthase. Bioorg Med Chem 22(1):398–405CrossRefPubMed

17.

Komisarenko SV, Sharykina NI, Lozynskyi MO, Lozynskyi MO, Karlova NP, Kudriavtseva IH, Kuzmenko IY, Borysevych AM, Yezerska LY (2001) Patent number UA 40714. Published 15.08.2001. Antitumor agent (mebiphon) Russian

Titel: Etidronic acid and its calcium-comprising complexes in the treatment of experimental osteoporosis in estrogen-deficient rats
verfasst von: V. V. Povoroznyuk
N. V. Grygorieva
V. I. Pekhnyo
H. Resch
O. M. Kozachkova
N. V. Tsaryk
Publikationsdatum: 01.03.2018
Verlag: Springer Vienna
Erschienen in: Journal für Mineralstoffwechsel & Muskuloskelettale Erkrankungen / Ausgabe 1/2018
Print ISSN: 2412-8260
Elektronische ISSN: 2412-8287
DOI: https://doi.org/10.1007/s41970-017-0018-x

Springer Medizin Österreich

Abstract

Aim

Materials and methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2018

Editorial

Zwei Kasuistiken zur Therapie mit Tofacitinib bei rheumatoider Arthritis

News-Screen Osteologie

Menopausale Hormontherapie 15 Jahre post WHI: Sicherheit geht vor

Fibröse Dysplasie

Mitteilungen des Magnesium- und Osteoporoseforums Bad Radkersburg